With new da­ta, As­traZeneca makes the case for its BTK in­hibitor in a first-line set­ting

Com­bined with chemother­a­py and im­munother­a­py, As­traZeneca’s Calquence re­duced the risk of dis­ease pro­gres­sion or death by 27% com­pared to place­bo and chemoim­munother­a­py in first-line man­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.